The factor that must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting sleep apnoea or death from sleep apnoea with the circumstances of a personâ€™s relevant service is: (a) for obstructive sleep apnoea only, (i) having chronic obstruction or chronic narrowing of the upper airway at the time of the clinical onset of sleep apnoea; or (ii) being obese at the time of the clinical onset of sleep apnoea; or (iii) having hypothyroidism at the time of the clinical onset of sleep apnoea; or (iv) having acromegaly at the time of the clinical onset of sleep apnoea; or (v) being treated with antiretroviral therapy for human immunodeficiency virus infection before the clinical onset of sleep apnoea; or (b) for central sleep apnoea only, (i) having congestive cardiac failure at the time of the clinical onset of sleep apnoea; or (ii) using a long-acting opioid at an average daily morphine equivalent dose of at least 75 milligrams for at least the two months before the clinical onset of sleep apnoea; or (c) having a central nervous system lesion or disorder involving the upper or mid-cervical cord, brain stem, cerebrum or extrapyramidal system at the time of the clinical onset of sleep apnoea; or (d) having autonomic neuropathy at the time of the clinical onset of sleep apnoea; or (e) having chronic renal disease requiring renal transplantation or dialysis at the time of the clinical onset of sleep apnoea; or (f) having a neuromuscular disease affecting the diaphragm, other respiratory muscles or upper airway muscles at the time of the clinical onset of sleep apnoea; or (g) being treated daily with an atypical antipsychotic drug, for a condition for which the drug cannot be ceased or substituted, for at least the two months before the clinical onset of sleep apnoea; or (h) for obstructive sleep apnoea only, (i) having chronic obstruction or chronic narrowing of the upper airway at the time of the clinical worsening of sleep apnoea; or (ii) being obese at the time of the clinical worsening of sleep apnoea; or (iii) having hypothyroidism at the time of the clinical worsening of sleep apnoea; or (iv) having acromegaly at the time of the clinical worsening of sleep apnoea; or (v) being treated with antiretroviral therapy for human immunodeficiency virus infection before the clinical worsening of sleep apnoea; or (i) for central sleep apnoea only, (i) having congestive cardiac failure at the time of the clinical worsening of sleep apnoea; or (ii) using a long-acting opioid at an average daily morphine equivalent dose of at least 75 milligrams for at least the two months before the clinical worsening of sleep apnoea; or (j) having a central nervous system lesion or disorder involving the upper or mid-cervical cord, brain stem, cerebrum or extrapyramidal system at the time of the clinical worsening of sleep apnoea; or (k) having autonomic neuropathy at the time of the clinical worsening of sleep apnoea; or (l) having chronic renal disease requiring renal transplantation or dialysis at the time of the clinical worsening of sleep apnoea; or (m) having a neuromuscular disease affecting the diaphragm, other respiratory muscles or upper airway muscles at the time of the clinical worsening of sleep apnoea; or (n) being treated daily with an atypical antipsychotic drug, for a condition for which the drug cannot be ceased or substituted, for at least the two months before the clinical worsening of sleep apnoea; or (o) consuming an average of at least 30 grams of alcohol per day for at least the six months before the clinical worsening of sleep apnoea; or (p) inability to obtain appropriate clinical management for sleep apnoea.